Search for a command to run...
No recent news available for this stock.
Conference call summary is not available for this stock.
Panjon Ltd. shows significant weaknesses in growth and profitability metrics compared to its peers in the Pharmaceuticals & Drugs sector. While it has a low debt-to-equity ratio, its revenue growth and profitability measures are poor, positioning it as an underperformer. Companies like Cipla Ltd. and Dr. Reddy's Laboratories Ltd. demonstrate stronger profitability and growth, making them sector leaders.
Strong revenue growth (13.28% YoY) and low PE ratio of 23.73, indicating both profitability and valuation attractiveness.
High ROE (21.76%) and low PE (15.50), showing excellent returns and reasonable valuation.
Highest revenue growth (18.12% YoY) and solid profitability metrics, making it a strong contender.